Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 56

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 56
---
 similar items of variable consideration, as applicable. (3) Adjusted EBITDA includes GAAP to non-GAAP adjustments to net loss, the most directly comparable GAAP financial measure, that reflect how the Company’s management analyzes its financial results. The adjusted EBITDA figures presented here are unlikely to be comparable with adjusted EBITDA disclosures released by other companies or us in other contexts, including due to the fact that for purposes of the cash LTIP, adjusted EBITDA includes adjustments related to net revenues and cost of goods sold for sales to our third-party partner for our liposome bupivacaine injectable suspension in veterinary use because we do not have any control over the timing or quantities of the third-parties’ sales or order patterns, and also excludes the accounting cost of the cash LTIP itself. In 2024, adjusted EBITDA for calculating performance under the cash LTIP also included adjustments to GAAP net loss by adding back interest expense, income tax expense, depreciation expense, amortization of acquired intangible assets, restructuring charges, acquisition- related charges, a loss on termination of a lease, stock-based compensation, former CEO transition costs, and a goodwill impairment, and by subtracting interest income, changes in the fair value of contingent consideration, and a gain on the early extinguishment of debt. Note : Performance and payouts in between levels is calculated on a straight-line basis.

Pacira BioSciences, Inc. 2025 Proxy Statement | 67

TABLE OF CONTENTS Executive Compensation

The performance against the two cash LTIP performance metrics is equally weighted to determine the potential award, which is then subject to the application of the relative TSR component. The relative TSR component based on the Company’s level of achievement against the companies comprising the S&P Pharmaceuticals Select Industry Index is applied to the earned payout resulting from the achievement of the performance metrics as follows:

| Percentile Ranking | ​ | ​ | ≤ 50th | ​ | ​ | 55th | ​ | ​ | 60th | ​ | ​ | 65th | ​ | ​ | 70th | ​ | ​ | ≥ 75th | ​ | ​ | ​ | Result12.0th | ​ |
| Payout Component   | ​ | ​ | 100%   | ​ | ​ | 110% | ​ | ​ | 120% | ​ | ​ | 130% | ​ | ​ | 140% | ​ | ​ | 150%   | ​ | ​ | ​